Evidence map›Paper›PMID 42022826›Full record

ArticleFrontiers in public health2026

Public knowledge, attitudes, and barriers to cancer screening in the UAE: a comprehensive assessment to inform screening practices.

Anan S Jarab, Walid Al-Qerem, Hamza Jarab, Omar Jrab, Rahma Elsherif, Ahmad Z Al Meslamani, Zelal Kharaba, Yazid Al Hamarneh, Maher Khdour, Nada A Alsaleh and 1 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anan S JarabDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Walid Al-QeremDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
Hamza JarabFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Omar JrabBarts and The London School of Medicine and Dentistry, Queen Mary University of London, Victoria, Malta.
Rahma ElsherifCollege of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates.
Ahmad Z Al MeslamaniCollege of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates.
Zelal KharabaDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
Yazid Al HamarnehDepartment of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Maher KhdourFaculty of Pharmacy, Al-Quds University, Jerusalem, Palestine.
Nada A AlsalehDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Salahdein AburuzDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives: Despite the proven benefits of early cancer detection in reducing disease-related complications and deaths, participation in cancer screening programs varies across population and is influenced by multiple individual and systemic-level factors. Understanding knowledge, attitudes and practices regarding cancer screening is essential to inform effective public health strategies, Therefore, this study aimed to assess these factors among adults in the UAE. Methods: A cross-sectional study was conducted using a bilingual (English/Arabic), self-administered online questionnaire distributed via social media. The survey collected data on socio-demographic characteristics, lifestyle-related risk factors, and cancer screening practices. Cancer knowledge was assessed using 59 items covering general knowledge, screenable cancers, warning signs and symptoms, and environmental risk factors. Attitudes perceived facilitators and barriers to screening were measured using a 5-point Likert scale. Screening behavior was assessed as self-reported lifetime ("ever") participation in any cancer screening test. Binary logistic regression analysis was performed to identify factors associated with screening practices. Results: A total of 811 individuals completed the study questionnaire, of whom only 36.5% reported having ever undergone any cancer screening test. Higher knowledge (OR = 1.022; 95% CI: 1.007-1.037) and more positive attitudes (OR = 1.091; 95% CI: 1.062-1.120) were associated with increased screening uptake. Older age (OR = 0.970; 95% CI: 0.955-0.985) and lower income (OR = 0.689; 95% CI: 0.483-0.982) were associated with a reduced likelihood of screening. Physician recommendation (47.0%) and early detection (45.3%) were the main motivators, while fear of results (39.5%), lack of symptoms (38.6%), and unfamiliarity with screening sites (38.5%) were the most common barriers. Conclusion: The findings demonstrate moderate cancer knowledge, variable screening attitudes, and multiple behavioral and system-level barriers. Knowledge, attitudes, age, and income, were significantly associated with lifetime screening participation, while physician recommendation and early detection emerged as key motivators. Targeted educational interventions and improved healthcare system navigation may enhance screening uptake in similar populations. However, findings should be interpreted with caution due to cross-sectional design, convenience sampling, reliance on self-reported lifetime screening, and the relatively young age distribution, which may limit causal inference and generalizability.

Indexed as

Early Detection of CancerHealth Knowledge, Attitudes, PracticeNeoplasmsAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedRisk FactorsSurveys and QuestionnairesUnited Arab EmiratesYoung Adultattitudesbarrierscancerknowledgemotivatorspublicscreening practices

Identifiers

PMID42022826
PMCPMC13095672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.